Results 151 to 160 of about 8,600 (184)

The siderophore transporter Sit1 is involved in the uptake of caspofungin by <i>Candida albicans</i>. [PDF]

Antimicrob Agents Chemother
Pedras A, Amaral C, Conceição C, Malta-Luís C, Pissarro T, V Mariano C, A Lenis-Rojas O, Ventura MR, Pimentel C.   +8 more
europepmc   +1 more source

Draft genome sequence and metabolomics data for <i>Streptomyces</i> sp. ADLamb9 isolated from the rhizosphere of <i>Lavandula dentata</i>. [PDF]

Data Brief
Dely A, Racicot R, Samples R, Giddings LA.   +3 more
europepmc   +1 more source

Epigenetic Dysregulation in Neurodegeneration: The Role of Histone Deacetylases and Emerging Inhibitor Strategies. [PDF]

Biomolecules
Pawar Y, Kopranovic A, C S R, Meyer-Almes FJ.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Recent non-hydroxamate matrix metalloproteinase inhibitors

Expert Opinion on Therapeutic Patents, 2005
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endo-peptidases that have the capacity to degrade all elements of the extracellular matrix (ECM) and are required for homeostatic maintenance of the ECM. Interest in MMPs arose from the accumulating evidence implying that over-activity of MMPs plays a role in mediating or accompanying a ...
Eli Breuer, Julia Frant, Reuven Reich
openaire   +1 more source

Rational Design of Non-Hydroxamate Histone Deacetylase Inhibitors

Mini-Reviews in Medicinal Chemistry, 2006
While most inhibitors of histone deacetylases (HDACs) are hydroxamic acid derivatives, several non-hydroxamates have recently been developed as inhibitors and attracted quite a deal of attention. In this review, we present the rational design, inhibitory effect and antiproliferative activity of non-hydroxamate HDAC inhibitors.
Takayoshi, Suzuki, Naoki, Miyata
openaire   +2 more sources

Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532

Bioorganic & Medicinal Chemistry, 2021
Infectious diseases caused by resistant Gram-negative bacteria have become a serious problem, and the development of therapeutic drugs with a novel mechanism of action and that do not exhibit cross-resistance with existing drugs has been earnestly desired.
Fumihito, Ushiyama, Hajime, Takashima, Yohei, Matsuda, Yuya, Ogata, Naoki, Sasamoto, Risa, Kurimoto-Tsuruta, Kaori, Ueki, Nozomi, Tanaka-Yamamoto, Mayumi, Endo, Masashi, Mima, Kiyoko, Fujita, Iichiro, Takata, Satoshi, Tsuji, Haruhiro, Yamashita, Hirotoshi, Okumura, Katsumasa, Otake, Hiroyuki, Sugiyama   +16 more
openaire   +2 more sources

Potent and Selective Non‐hydroxamate Histone Deacetylase 8 Inhibitors

ChemMedChem, 2016
AbstractSpecific inhibition of histone deacetylase 8 (HDAC8) has been suggested as a promising option for the treatment of neuroblastoma and T‐cell malignancies. A novel class of highly potent and selective HDAC8 inhibitors with a pyrimido[1,2‐c][1,3]benzothiazin‐6‐imine scaffold was studied that is completely different from the traditional concept of ...
Kleinschek, Alexander, Meyners, Christian, Digiorgio, Eros, BRANCOLINI, Claudio, Meyer almes, Franz josef   +4 more
openaire   +3 more sources

Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors

Bioorganic & Medicinal Chemistry Letters, 2005
Inhibitors of histone deacetylases (HDAC) are emerging as a promising class of anti-cancer agents. A mercaptoamide functionality was designed as a bidentate zinc chelator and incorporated into the hydroxamic acid based SAHA (1) scaffold in order to identify non-hydroxamate compounds as potential inhibitors of histone deacetylases.
Sampath-Kumar, Anandan, John S, Ward, Richard D, Brokx, Mark R, Bray, Dinesh V, Patel, Xiao-Xi, Xiao   +5 more
openaire   +2 more sources